ad image

Q12023

1 / 1
Supporting Drug Development – Increasing Probability of Success
Consulting

Supporting Drug Development – Increasing Probability of Success

Nick Davies; Beth Lindsey; Ian Smart

Verta Life Sciences

PAO-03-23-CL-04Mar 24, 2023
Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies
Tumor Microenvironment

Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies

Gil Efron

Purple Biotech

PAO-03-23-CL-01Mar 21, 2023
A Novel Technology Platform for Bone Regeneration and Cancer Treatment
Bone Regeneration

A Novel Technology Platform for Bone Regeneration and Cancer Treatment

Denis Dufrane, M.D., Ph.D.

PAO-03-23-CL-06Mar 20, 2023
Helping Clinicians Make Better Decisions More Easily
Point of Care

Helping Clinicians Make Better Decisions More Easily

Matt Titus

epocrates

PAO-03-23-CL-05Mar 16, 2023
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

Chris Berger; Kilian Witzel

Avid Bioservices

PAO-02-23-CL-03Mar 14, 2023
The Powerful Potential of Digital Twin Technology to Improve Drug Discovery, Development, Manufacturing, and More
Digital Twin Technology

The Powerful Potential of Digital Twin Technology to Improve Drug Discovery, Development, Manufacturing, and More

David Alvaro, Ph.D.

Pharma's Almanac

PAO-03-23-NI-02Mar 07, 2023
Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down
FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-23-NI-03Mar 07, 2023
The Opportunities and Challenges Posed by Biosimilar Interchangeability
Interchangeable Biosimilars

The Opportunities and Challenges Posed by Biosimilar Interchangeability

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-23-NI-01Mar 07, 2023
Scale-Up Expertise to Support Your Biologics Life Cycle
Scale-Up

Scale-Up Expertise to Support Your Biologics Life Cycle

Pramthesh (Prem) Patel, Ph.D.

Avid Bioservices

PAO-02-23-CL-06Mar 02, 2023
The Right Materials for Success in Bioprinting
Bioprinting

The Right Materials for Success in Bioprinting

Elena Meurer; Mariya Gromova

Biopharma Excellence

PAO-02-23-CL-05Feb 15, 2023
Early Reports of Positive Experiences with EMA’s New Clinical Trials Information System
Clinical Trials

Early Reports of Positive Experiences with EMA’s New Clinical Trials Information System

Kieran O’Donnell; Nicola Kidman

PAO-02-23-CL-02Feb 15, 2023
Lipid Nanoparticles: Transforming the Nanomedicines Market
Lipid Nanoparticles

Lipid Nanoparticles: Transforming the Nanomedicines Market

Antonio Costa, Ph.D.

DIANT Pharma

PAO-02-23-CL-01Feb 07, 2023
From Llamas to Yeast: Producing Functional Therapeutic Antibody Fragments in Saccharomyces cerevisiae
Antibody Production

From Llamas to Yeast: Producing Functional Therapeutic Antibody Fragments in Saccharomyces cerevisiae

Phenotypeca

PAO-01-23-CL-05-153Feb 01, 2023
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
Gene Tools

Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos

David Alvaro, Ph.D.; Jon Moulton, Ph.D.

Pharma's Almanac

PAO-01-23-CL-05Feb 01, 2023
Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles
Cell Therapy

Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-01-23-NI-01Jan 31, 2023
Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development
Anti-Idiotype Antibodies

Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development

Na Li, Ph.D.

Sino Biological

PAO-01-23-CL-01Jan 13, 2023
1 / 1